Aytu BioPharma (AYTU) Q4 2026 earnings review
Legacy bounce and EXXUA ramp halt cash burn, but margins slip
Aytu returned to top-line growth, generating $16.1 million in Q4 revenue for a 6.4% YoY increase. EXXUA contributed $3.9 million in its first full quarter, supported by prescriptions surging 138% sequentially to 3,323. Adjusted EBITDA swung back to a positive $0.5 million, and net loss narrowed to an optically clean break-even, though the bottom line benefited from a $1.0 million non-cash warrant gain. Gross margins, however, compressed 3.2 points to 64.6%.
⚖️ Verdict: 🟢 Bullish
The case is better — a bullish verdict — because the legacy ADHD portfolio stabilized sequentially and provided enough cash to fund the commercial launch without further draining the balance sheet. By avoiding a structural cash burn, management proved it could navigate the generic transition while scaling its new psychiatric asset, allowing the narrative to stay focused on EXXUA's rapid early adoption.
What the print did not settle is where EXXUA's normalized unit economics will land once the free-trial and guarantee programs roll off. The next two quarters of revenue matched against prescription volume will provide the reading.
🐂 Bull Case
EXXUA Ramp Gains Velocity
The early traction for the company's major depressive disorder launch accelerated in its first full quarter. Prescriptions jumped 138% sequentially to 3,323, pushing EXXUA net revenue to $3.9 million. This establishes the new psychiatric asset at roughly a quarter of the company's total revenue mix, proving the specialized sales force can convert interest into dispensing volume even as the legacy business shrinks.
The number to watch is the sequential growth in prescriptions next quarter, as the initial 14-day free titration packs convert into maintenance prescriptions and test patient retention.
The Legacy Cash Engine Restarts
The immediate threat to the balance sheet from last quarter's deep revenue shortfall has eased. After ADHD portfolio revenues dropped to $9.1 million in Q3, raising fears that generic competition was draining cash too quickly to fund the EXXUA launch, the segment rebounded sequentially to $10.4 million. That stabilization flipped Adjusted EBITDA back to a positive $0.5 million and halted the cash burn, leaving the cash balance virtually flat at $26.3 million.
🐻 Bear Case
Core Operations Deteriorated When Stripping Out Impairments
Management cites the quarter as evidence of operating leverage, but the clean unit economics point the other way. Once last year's $8.3 million non-cash impairment is stripped out of the comparison period, the clean operating margin actually fell by 9.1 points YoY, dropping from a positive 4.2% to a negative 4.8% (derived).
The margin erosion comes from the top and the bottom: gross margins contracted 3.2 points to 64.6%, while selling and marketing expense consumed 38.0% of revenue, up 6.4 points YoY. The company is funding its growth by spending a larger share of a shrinking gross profit dollar.
The ADHD Drag Remains Pronounced YoY
The sequential bounce in the ADHD segment covers up a structural decline. The portfolio's revenue remains down 21.0% against a year ago, ensuring that total corporate revenue only scraped out 6.4% growth despite EXXUA adding nearly $4 million. With generic competition active and promotional support removed, the legacy base will continue to offset a significant portion of EXXUA's new dollars.
Standing risks the print did not read on
Several details governing the profitability of the new launch remain undisclosed:
- Gross-to-net stabilization: no explicit target for the terminal discount rate once the free titration and 60-day guarantee programs run off.
- Commercial payer mix: no breakdown of the share of scripts covered by commercial insurance versus government programs, which dictates final reimbursement.
💲 Other KPIs
Up 28.0% YoY, representing 38.0% of revenue. The increase reflects planned commercialization investments to deploy the dedicated sales force for EXXUA.
Bounced 96.5% sequentially as supply disruptions resolved, but remains down 10.3% against a year ago due to the strategic deemphasis of the segment.
🔮 Guidance
Management expects to build toward more consistent positive Adjusted EBITDA levels as fiscal 2027 progresses. The directional guide relies on scaling EXXUA revenues to overtake the drag from the legacy portfolios.
❓ Key Questions
Normalized Net Pricing
What is the expected steady-state gross-to-net discount for EXXUA once the initial friction-removing programs—such as the free 14-day titration pack—run off?
Payer Mix Evolution
What proportion of the 3,323 Q4 prescriptions fell under commercial insurance versus mandated government coverage, and how does that split affect the path to profitability?
Adzenys Market Share
With the authorized generic strategy in place, what is the current market share of the Teva generic, and how much further price matching is required to defend the RxConnect volume?